LLY

1,049.88

-0.62%↓

JNJ

204.6

-0.79%↓

ABBV

223.87

-0.13%↓

UNH

324.26

-0.63%↓

AZN

90.38

-0.32%↓

LLY

1,049.88

-0.62%↓

JNJ

204.6

-0.79%↓

ABBV

223.87

-0.13%↓

UNH

324.26

-0.63%↓

AZN

90.38

-0.32%↓

LLY

1,049.88

-0.62%↓

JNJ

204.6

-0.79%↓

ABBV

223.87

-0.13%↓

UNH

324.26

-0.63%↓

AZN

90.38

-0.32%↓

LLY

1,049.88

-0.62%↓

JNJ

204.6

-0.79%↓

ABBV

223.87

-0.13%↓

UNH

324.26

-0.63%↓

AZN

90.38

-0.32%↓

LLY

1,049.88

-0.62%↓

JNJ

204.6

-0.79%↓

ABBV

223.87

-0.13%↓

UNH

324.26

-0.63%↓

AZN

90.38

-0.32%↓

Начало・Списък с акции・Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc

Отворен

СекторЗдравеопазване

43 -0.78

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

41.77

Максимум

43.68

Ключови измерители
By Trading Economics
Приходи	-6.2M -91M
Марж на печалбата	-867.293
Служители	316
EBITDA	4M -90M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+24.31% upside

Пазарни показатели
By TradingEconomics
Пазарна капитализация	19M 3.2B
Предишно отваряне	43.78
Предишно затваряне	43

Настроения в новините

By Acuity

50%

166 / 374 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bearish Evidence

34.81 / 38.24 Подкрепа & съпротива

Xenon Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

1.12.2025 г., 21:16 ч. UTC

Придобивния, сливания и поглъщания

Marsh McLennan Agency Acquires Three Hawaii-Based Insurance Brokerages

1.12.2025 г., 18:51 ч. UTC

Значими двигатели на пазара

Shopify Stock Falls on Cyber Monday System Outages

1.12.2025 г., 23:47 ч. UTC

Пазарно говорене

Nikkei May Rise on Bargain Hunting -- Market Talk

1.12.2025 г., 23:27 ч. UTC

Придобивния, сливания и поглъщания

Genting Bhd. Stake in Genting Malaysia Now at 73.13% Vs. 49.36% Ahead of Take Private Offer Made in October

1.12.2025 г., 23:26 ч. UTC

Придобивния, сливания и поглъщания

Genting Bhd.: Offer to Take Genting Malaysia Private Closed on Dec.1

1.12.2025 г., 23:25 ч. UTC

Придобивния, сливания и поглъщания

Bitcoin Rout Picks Up Steam as Investors Fret Over a New 'Crypto Winter' -- WSJ

1.12.2025 г., 21:52 ч. UTC

Придобивния, сливания и поглъщания

Wood Partners Announces Itochu Corp. Purchase of 19.5% of Wood Partners

1.12.2025 г., 21:42 ч. UTC

Придобивния, сливания и поглъщания

Goldman's Latest Acquisition Is a $2 Billion Bet on Active ETFs -- Barrons.com

1.12.2025 г., 21:41 ч. UTC

Пазарно говорене

Canada's GDP Revisions Mean Lower Debt-to-GDP Ratio, Better Productivity -- Market Talk

1.12.2025 г., 21:41 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

1.12.2025 г., 21:41 ч. UTC

Пазарно говорене

Canada's GDP Revisions Mean Lower Debt-to-GDP Ratio, Better Productivity -- Market Talk

1.12.2025 г., 21:17 ч. UTC

Придобивния, сливания и поглъщания

Commercial Metals Expects to Close Foley Products Deal by End of 2025 >CMC

1.12.2025 г., 21:17 ч. UTC

Придобивния, сливания и поглъщания

Commercial Metals Completes Acquisition of Concrete Pipe & Precast for $675M Cash >CMC

1.12.2025 г., 21:15 ч. UTC

Придобивния, сливания и поглъщания

Commercial Metals Completes Acquisition Of Concrete Pipe & Precast, LLC >CMC

1.12.2025 г., 20:15 ч. UTC

Пазарно говорене

Natural Gas Turns Positive Amid Mixed Weather Trends -- Market Talk

1.12.2025 г., 20:00 ч. UTC

Придобивния, сливания и поглъщания

Marsh McLennan Agency Acquires Three Hawai'i-based Insurance Brokerages >MMC

1.12.2025 г., 18:54 ч. UTC

Пазарно говорене

Silver Hits New Record As Momentum Continues -- Market Talk

1.12.2025 г., 18:46 ч. UTC

Пазарно говорене

Luxury Seen With Accelerating Growth Next Year -- Market Talk

1.12.2025 г., 16:41 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

1.12.2025 г., 16:41 ч. UTC

Пазарно говорене

Rapid Wage Growth in Canada to Keep BOC Sidelined -- Market Talk

1.12.2025 г., 16:20 ч. UTC

Пазарно говорене

Yen Could Strengthen Further Against Dollar on Rate-Hike Prospects -- Market Talk

1.12.2025 г., 16:00 ч. UTC

Печалби

Strategy Helped Solve Its Bitcoin-Preferred Problem. Here's How. -- Barrons.com

1.12.2025 г., 15:51 ч. UTC

Придобивния, сливания и поглъщания

Goldman Makes a $2 Billion Bet on 'Boomer Candy' -- WSJ

1.12.2025 г., 15:47 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

1.12.2025 г., 15:47 ч. UTC

Пазарно говорене

Airbus Guidance Is at Risk -- Market Talk

1.12.2025 г., 15:46 ч. UTC

Придобивния, сливания и поглъщания

Synopsys Gets a New Investor. What to Know About Nvidia's Stake. -- Barrons.com

1.12.2025 г., 15:33 ч. UTC

Пазарно говорене

Airbus Selloff May Be Overdone -- Market Talk

1.12.2025 г., 15:26 ч. UTC

Пазарно говорене

Warming Forecast Pressures Natural Gas -- Market Talk

1.12.2025 г., 15:23 ч. UTC

Пазарно говорене

Geopolitical Turmoil Supports Crude Oil -- Market Talk

1.12.2025 г., 14:59 ч. UTC

Придобивния, сливания и поглъщания

Goldman's Latest Acquisition Is a $2 Billion Bet on Active ETFs -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

Xenon Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

24.31% нагоре

12-месечна прогноза

Среден 55.59 USD 24.31%

Висок 65 USD

Нисък 44 USD

Според 14 анализатори от Wall Street, предложили 12-месечна ценова цел за Xenon Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

14 ratings

Купи

Задържане

Продай

Според 14 анализатори, дали борсови рейтинги на Xenon Pharmaceuticals Inc през последните 3 месеца.

Техническа оценка

By Trading Central

34.81 / 38.24Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Настроение

By Acuity

166 / 374 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.